Evidence map›Paper›PMID 33552729›Full record

ArticlePeerJ2021

Patients with coronary heart disease, dilated cardiomyopathy and idiopathic ventricular tachycardia share overlapping patterns of pathogenic variation in cardiac risk genes.

Christian Guelly, Zhannur Abilova, Omirbek Nuralinov, Katrin Panzitt, Ainur Akhmetova, Saule Rakhimova, Ulan Kozhamkulov, Ulykbek Kairov, Askhat Molkenov, Ainur Seisenova and 8 more

Open access · goldAbstract read
In one paragraph

Article in PeerJ, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.8field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Functional Profiling ofCirculation. Genomic and precision medicine · 2025
    Article
  3. Review
  4. Article
  5. Significance of α-Myosin Heavy Chain (Journal of cardiovascular development and disease · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 4 institutions in 3 countries.

Christian Guelly *Center of Medical Research, Medical University of Graz, Graz, Austria.
Zhannur AbilovaLaboratory of Genomic and Personalized Medicine, Center for Life Science, National Laboratory Astana, Nazarbayev University, Nur-Sultan, Kazakhstan.
Omirbek NuralinovNational Research Cardiac Surgery Center, Nur-Sultan, Kazakhstan.
Katrin PanzittCenter of Medical Research, Medical University of Graz, Graz, Austria.
Ainur AkhmetovaLaboratory of Genomic and Personalized Medicine, Center for Life Science, National Laboratory Astana, Nazarbayev University, Nur-Sultan, Kazakhstan.
Saule RakhimovaLaboratory of Genomic and Personalized Medicine, Center for Life Science, National Laboratory Astana, Nazarbayev University, Nur-Sultan, Kazakhstan.
Ulan KozhamkulovLaboratory of Genomic and Personalized Medicine, Center for Life Science, National Laboratory Astana, Nazarbayev University, Nur-Sultan, Kazakhstan.
Ulykbek KairovLaboratory of Bioinformatics and Systems Biology, Center for Life Sciences, National Laboratory Astana, Nazarbayev University, Nur-Sultan, Kazakhstan.
Askhat MolkenovLaboratory of Bioinformatics and Systems Biology, Center for Life Sciences, National Laboratory Astana, Nazarbayev University, Nur-Sultan, Kazakhstan.
Ainur SeisenovaLaboratory of Bioinformatics and Systems Biology, Center for Life Sciences, National Laboratory Astana, Nazarbayev University, Nur-Sultan, Kazakhstan.
Slave TrajanoskiCenter of Medical Research, Medical University of Graz, Graz, Austria.
Gulzhaina Abildinova RashbayevaNational Research Cardiac Surgery Center, Nur-Sultan, Kazakhstan.
Galina KaussovaKazakhstan medical university "KSPH", Almaty, Kazakhstan.
Christian WindpassingerInstitute of Human Genetics, Medical University of Graz, Graz, Austria.
Joseph H LeeSergievsky Center Taub Institute, Columbia University Medical Center, New York, NY, United States of America.
Zhaxybay ZhumadilovLaboratory of Genomic and Personalized Medicine, Center for Life Science, National Laboratory Astana, Nazarbayev University, Nur-Sultan, Kazakhstan.
Makhabbat BekbossynovaNational Research Cardiac Surgery Center, Nur-Sultan, Kazakhstan.
Ainur Akilzhanova *Laboratory of Genomic and Personalized Medicine, Center for Life Science, National Laboratory Astana, Nazarbayev University, Nur-Sultan, Kazakhstan.
Nazarbayev University · KZMedical University of Graz · ATColumbia University Irving Medical Center · USKazakhstan Medical University · KZ

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundVentricular tachycardia (VT) is a major cause of sudden cardiac death (SCD). Clinical investigations can sometimes fail to identify the underlying cause of VT and the event is classified as idiopathic (iVT). VT contributes significantly to the morbidity and mortality in patients with coronary artery disease (CAD) and dilated cardiomyopathy (DCM). Since mutations in arrhythmia-associated genes frequently determine arrhythmia susceptibility screening for disease-predisposing variants could improve VT diagnostics and prevent SCD in patients.

methodsNinety-two patients diagnosed with coronary heart disease (CHD), DCM, or iVT were included in our study. We evaluated genetic profiles and variants in known cardiac risk genes by targeted next generation sequencing (NGS) using a newly designed custom panel of 96 genes. We hypothesized that shared morphological and phenotypical features among these subgroups may have an overlapping molecular base. To our knowledge, this was the first study of the deep sequencing of 96 targeted cardiac genes in Kazakhstan. The clinical significance of the sequence variants was interpreted according to the guidelines developed by the American College of Medical Genetics and Genomics (ACMG) and the Association for Molecular Pathology (AMP) in 2015. The ClinVar and Varsome databases were used to determine the variant classifications.

resultsTargeted sequencing and stepwise filtering of the annotated variants identified a total of 307 unique variants in 74 genes, totally 456 variants in the overall study group. We found 168 mutations listed in the Human Genome Mutation Database (HGMD) and another 256 rare/unique variants with elevated pathogenic potential. There was a predominance of high- to intermediate pathogenicity variants in

conclusionsIn this study we showed that in patients with VT secondary to coronary artery disease, DCM, or idiopathic etiology multiple rare mutations and clinically significant sequence variants in classic cardiac risk genes associated with cardiac channelopathies and cardiomyopathies were found in a similar pattern and at a comparable frequency.

Indexed as

96 cardiac genes panelACMGCoronary heart diseaseDilated cardiomyopathyGenetic variantHGMDNext generation sequencingPathogenesisTargeted sequencingVentricular tachycardia

Identifiers

PMID33552729
PMCPMC7821765
OpenAlexW3123470841

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.